Literature DB >> 17127436

A role for procarboxypepidase U (TAFI) in thrombosis.

Johan L Willemse1, Dirk F Hendriks.   

Abstract

The maintenance of the equilibrium between coagulation and fibrinolysis is crucial for normal haemostasis. In contrast, pathologic consequences of imbalance manifest tendencies of bleeding or thrombosis. Procarboxypeptidase U (proCPU, TAFI) is recognized as an important link between the coagulation system and fibrinolysis. Following activation by thrombin (IIa), carboxypeptidase U (CPU) exerts an antifibrinolytic effect by abolishing the cofactor function of partially degraded fibrin in plasminogen (Pg) activation. This review article focuses on the role of the proCPU/CPU system in the balance between fibrin deposition and removal. How a disturbed system can lead to a higher thrombotic tendency is discussed, while CPU inhibition as a new drug target for fibrinolytic therapy is extensively reviewed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17127436     DOI: 10.2741/2203

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  7 in total

1.  Measuring the mechanical properties of blood clots formed via the tissue factor pathway of coagulation.

Authors:  J H Foley; S Butenas; K G Mann; K E Brummel-Ziedins
Journal:  Anal Biochem       Date:  2012-01-03       Impact factor: 3.365

2.  Total synthesis of (+/-)- and (-)-actinophyllic acid.

Authors:  Connor L Martin; Larry E Overman; Jason M Rohde
Journal:  J Am Chem Soc       Date:  2010-04-07       Impact factor: 15.419

3.  Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis.

Authors:  Paul Y Kim; Paula Y G Kim; Fletcher B Taylor; Michael E Nesheim
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

4.  The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa.

Authors:  Kanchan Anand; Irantzu Pallares; Zuzana Valnickova; Trine Christensen; Josep Vendrell; K Ulrich Wendt; Herman A Schreuder; Jan J Enghild; Francesc X Avilés
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

Review 5.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

6.  The X-ray structure of carboxypeptidase A inhibited by a thiirane mechanism-based inhibitor.

Authors:  Daniel Fernández; Sebastian Testero; Josep Vendrell; Francesc X Avilés; Shahriar Mobashery
Journal:  Chem Biol Drug Des       Date:  2009-11-04       Impact factor: 2.817

Review 7.  Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

Authors:  Karen Claesen; Joachim C Mertens; Dorien Leenaerts; Dirk Hendriks
Journal:  Int J Mol Sci       Date:  2021-01-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.